Albion Technology & General VCT PLC Interim Management Statement Overview
Introduction
We delve into the interim management statement of Albion Technology & General VCT PLC, spotlighting the period extending from January to March of the current year. Understanding the company’s latest moves can inform investors and stakeholders regarding its financial health and strategic direction.
Financial Performance Review
The Company reported a commendable unaudited net asset value (NAV) of £274.8 million, translating to 73.51 pence per share by the end of March. This marks an increase of 0.6% or 0.47 pence per share since the prior quarter ended in December. This positive movement showcases the company's resilience even amidst the broader market fluctuations.
Recent Fundraising Efforts
In early January, the Albion Technology & General VCT launched a prospectus Top Up Offer for new ordinary shares, indicating its commitment to bolster capital and expand its investment capabilities. By the end of March, the Board announced that they successfully reached the £30 million limit of the subscription offer, emphasizing a strong investor response and confidence in the company's strategy. This was bolstered by an additional facility of £10 million for over-allotments as the demand for shares remained robust.
Investment Portfolio Developments
Throughout the reporting period, Albion Technology made several notable investments that signify a diverse portfolio aligned with innovative trends.
New Capital Injections
Significant fresh investments include:
- Latent Technology Group: Investing £1,722,000 in their animation utilizing reinforcement learning technology.
- Innerworks Technology: A £350,000 investment focusing on adaptive security solutions.
- Scripta Therapeutics: Allocating £274,000 towards AI-driven drug discovery processes.
- OtoImmune: Investing £172,000 in technology aimed at the detection and treatment of autoimmune diseases.
- Pastel Health: A commitment of £97,000 towards supporting digital multi-specialty care providers.
- Formicor Pharmaceuticals: Investing £55,000 in innovative drug reformulation efforts.
Further Portfolio Enhancements
In addition to new investments, the company also made further investments amounting to:
- Mondra Global: £1,273,000 in food supply chain emissions modeling.
- TransFICC: £1,097,000 for a financial connectivity solution.
- Runa Network: A £90,000 investment in a platform for digital incentives and payouts.
- NuvoAir Holdings: Infusing £71,000 into digital therapeutics for respiratory health.
The total investments made during this timeframe reached approximately £5,260,000, demonstrating the company’s proactive approach in nurturing cutting-edge technology enterprises.
Top Holdings Overview
As of March 31, the top ten holdings reflect a strategic alignment with technology-driven sectors:
- Quantexa: With a carrying value of £51,401,000, approximately 18.7% of the NAV, being a leader in network analytics for financial crime detection.
- Proveca: An investment valued at £18,414,000, known for reformulating medicines for children, representing 6.7% of the NAV.
- Gravitee Topco: £9,259,000 invested in API management, representing 3.4% of the NAV.
These stakes highlight the focus on ensuring a robust financial technology landscape as well as health innovation.
Buy-back Policies and Strategic Direction
Although no share buy-backs have occurred during this reporting period due to the Company's close period constraints, the Board reaffirms its ongoing strategy to pursue buy-backs at around a 5% discount to the net asset value, emphasizing ongoing value creation for shareholders.
Outlook and Strategic Direction
Looking ahead, further investment strategies have been laid out, particularly concerning the company's portfolio management and investment in sustainable technologies. The company continues to thrive as it expands its investment focus into growing sectors benefiting from digital transformation and sustainability, aligning with broader market trends and investor expectations.
Frequently Asked Questions
What is the current net asset value of Albion Technology & General VCT PLC?
The current unaudited net asset value is £274.8 million, equating to 73.51 pence per share.
When did the recent Top Up Offer open?
The Top Up Offer opened on January 6 of the current year.
What is the focus of Albion Technology's new investments?
The focus includes areas such as reinforcement learning for animation, adaptive security, AI drug discovery, and digital healthcare solutions.
Does the company buy back shares?
Yes, the company has a policy to buy back shares in line with its investment interests, however, no shares were bought back in the reviewed period due to a close period constraint.
How much capital was raised through the recent share offering?
The company successfully raised £30 million through its latest share offering, showcasing strong demand from investors.
